The primary purpose of the Organic Synthesis Facility (OSF) is to produce the highest quality synthetic molecules for Fox Chase Cancer Center (FCCC) investigators. The OSF was used by 19 investigators with peer-reviewed funding in calendar year 2009. Over eighty-five percent (85.4%) of use was in support of peer-reviewed, funded investigators in calendar year 2009. Small organic molecules are used in many areas of research as specific reagents including those that are inhibitors of enzyme activity or protein binding. Some of these molecules have been used in the development of prodrugs against target proteins identified at FCCC. Analogues of natural substrates have been used to probe enzyme mechanism, to investigate protein function, or to lest specific hypotheses. The molecules synthesized by the Facility are not purchasable from chemical companies, and custom synthesis from commercial enterprises is either not available or prohibitively expensive. The demand for synthetic services and especially the demand for novel compound synthesis have increased significantly over this current funding period. In order to meet this need, the efficiency and productivity of the Facility have been increased with the addition of a seasoned Ph.D. chemist to the staff and by acquisition of a new LC-MS system. In addition to increasing efficiency, the LC-MS system provides the Facility with new capabilities and services. During the last grant period (calendar years 2006-2009), 79 different chemical syntheses were completed including 44 novel compounds for 17 investigators in four Research Programs. The compounds synthesized were very diverse in structure and included a series of tamoxifen analogues, drug-conjugated antibodies, p53 inhibitors, Paki inhibitors, and photosensitizers. The OSF provided analytical, purification and consulting services to 46 investigators from all five Research Programs and seven Shared Facilities during the current funding period. In the last four calendar years (2006-2009), the average number of requests for these analytical and purification services was 59 per month, compared to 34 in calendar years 2000-2004. The large user group of 46 investigators from all five Research Programs and seven Shared Facilities indicates that the materials produced and services provided by the Facility are necessary for the scientific objectives of a wide range of research projects being carried out throughout the Center.

Public Health Relevance

Macromolecular interactions are central to all biological processes, including those involved in the development of cancer. These interactions either directly involve small organic molecules or can be modified by them. Modern biological research therefore requires the availability of organic compounds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
7P30CA006927-50
Application #
8475339
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
50
Fiscal Year
2013
Total Cost
$23,949
Indirect Cost
Name
Research Institute of Fox Chase Cancer Center
Department
Type
DUNS #
064367329
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Heckman, Carolyn J; Handorf, Elizabeth A; Darlow, Susan D et al. (2016) An Online Skin Cancer Risk-Reduction Intervention for Young Adults: Mechanisms of Effects. Health Psychol :
Boland, Patrick M; Meyer, Joshua E; Berger, Adam C et al. (2016) Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. Am J Clin Oncol :
Hayakawa, K; Formica, A M; Colombo, M J et al. (2016) Loss of a chromosomal region with synteny to human 13q14 occurs in mouse chronic lymphocytic leukemia that originates from early-generated B-1 B cells. Leukemia 30:1510-9
Meropol, Neal J; Wong, Yu-Ning; Albrecht, Terrance et al. (2016) Randomized Trial of a Web-Based Intervention to Address Barriers to Clinical Trials. J Clin Oncol 34:469-78
Duong-Ly, Krisna C; Devarajan, Karthik; Liang, Shuguang et al. (2016) Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases. Cell Rep 14:772-81
Tan, Yinfei; Xin, Xiaoban; Coffey, Francis J et al. (2016) Appl1 and Appl2 are Expendable for Mouse Development But Are Essential for HGF-Induced Akt Activation and Migration in Mouse Embryonic Fibroblasts. J Cell Physiol 231:1142-50
Geynisman, Daniel M; Handorf, Elizabeth; Wong, Yu-Ning et al. (2016) Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma. Cancer Med 5:192-9
Meeker, Caitlin R; Geynisman, Daniel M; Egleston, Brian L et al. (2016) Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer. J Oncol Pract 12:e755-64
Borczuk, Alain C; Pei, Jianming; Taub, Robert N et al. (2016) Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration. Cancer Biol Ther 17:328-35
Kurimchak, Alison M; Shelton, Claude; Duncan, Kelly E et al. (2016) Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer. Cell Rep 16:1273-86

Showing the most recent 10 out of 884 publications